My focus is really around the phase II trial partnership with Genentech to use Erivedge in the treatment of AML and high risk MDS. The opportunity for Erivedge in non-cancer related illness is enormous. And, I expect to see some updates in the progress into that area.
What data did you have in mind? I would settle for news of the completion of the dose escalation stage of the phase 1 study in CUDC-907, a commitment to present CUDC-907 data at ASH conference in December with the expectation it will show more PRs than just the one reported at the last ASH conference.
If he was buying stock having knowledge of any potential positive event, then he might have a problem. Ever heard of Insider trading?????
Mark my post , with the whisper I am hearing and the CEO buying 65k shares on the open market, you can take it to the bank.......BIG NEWS starting next week. Look for a price range 2.75-3.50
Why the massive revenues posted by REVI could lift the stock pass the $1.00 mark and deliver a shock to Wall Street. Management confirms $1,089,370.00 sales for Q2 2014
When is the volume going to pick upmy new buys 1 month ago cris geva and ambi cris when r u going to get out of the funk i am not losing muxh but the no volume thing is a debbie downer
Of course, anyday. IPF may change the CRIS life (and the patients, the more important thing).
Some shorts tried to say Roche had cancel the trial.
HO HO HO
Sentiment: Strong Buy